Health Condition 1: null- Primary and Secondary Infertility
Conditions
Interventions
Intervention1: Atosiban: Atosiban is an oxytocin receptor antagonist.0.9 ml of 6.75mg/ml Atosiban injection is given as an intervenous bolus 30 minutes prior to embryo transfer. An infusion of Atosiba
Sponsors
Infertility Department
Ajanta Hospital IVF Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients >= 23 years of age 2. Body mass index (BMI) of 18.5-38 kg per m2 at screening 3. Normal uterine cavity shown on ultrasound scanning 4. At least one good quality embryo for transfer 5. Basal FSH hormone concentration less than 10 IU/l 6. Patients undergoing IVF-ET using egg donation 7. Patients willing to give written informed consent and willing to comply with the clinical study protocol
Exclusion criteria
Exclusion criteria: 1. Patients >= 45 years of age 2. Uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, uncorrected hydrosalpinges, adenomyosis) 3. Risk of ovarian hyperstimulation syndrome 4. Patients with a known history of hypersensitivity to the study medication 5. Endocrine disorders (uncorrected thyroid disorders, hyperprolactinaemia) 6. Major organ disorders like liver or kidney failure 7. Patients who are otherwise judged inappropriate for inclusion in the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of atosiban in improving the implantation rate (IR) and clinical pregnancy rate (CPR) after embryo transfer.Timepoint: 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety of atosiban in enrolled patients exposed to the drugTimepoint: 4 months | — |
Countries
India
Contacts
Public ContactDr Shweta Shingvi
Ajanta Hospital and IVF Centre
Outcome results
None listed